Capricor Therapeutics, Inc. Class Action Lawsuit - CAPR

Company
Capricor Therapeutics, Inc. (NASDAQ: CAPR)
Class Period
May 8, 2020 - May 8, 2025

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines

WhatsApp

Scan the QR code or click the button to join

Join on WhatsApp

Get Updates by Email

Required Field

Required Field

Required Field

No Spam, opt-out anytime, alert list is free

Allegations

The filed complaint alleges that Capricor Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. Following this news, Capricor's stock price fell over 29% on May 6, 2025.

Eligibility

In order to be eligible to join the CAPR class action lawsuit, you must have incurred a loss on shares of Capricor Therapeutics, Inc. purchased during the class period listed above.

TOP